RAPP
NASDAQ HealthcareRapport Therapeutics, Inc. - Common Stock
Biotechnology
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
�� 市场数据
| 价格 | $39.71 |
|---|---|
| 成交量 | 1,657,343 |
| 市值 | 1.90B |
| RSI（14日） | 90.5 超买 |
| 200日均线 | $25.19 |
| 50日均线 | $30.15 |
| 52周最高 | $42.27 |
| 52周最低 | $7.73 |
| Forward P/E | -10.16 |
| Price / Book | 3.91 |
🎯 投资策略评分
RAPP 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (94/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 RAPP in your text
粘贴任何文章、记录或帖子 — 工具将提取 RAPP 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.